Virtual Library
Start Your Search
M.V. Pacchiana
Author of
-
+
P1.04 - Clinical Design, Statistics and Clinical Trials (ID 690)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Clinical Design, Statistics and Clinical Trials
- Presentations: 1
- Moderators:
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.04-002 - Tolerability of Osimertinib and Its Impact on Quality of Life in Advanced Non-Small Cell Lung Cancer Patients: The ARPA Study (ID 8081)
09:30 - 09:30 | Author(s): M.V. Pacchiana
- Abstract
Background:
Osimertinib is a potent Epidermal Growth Factor Receptor (EGFR) inhibitor, conferring a longer survival if compared to platinum-pemetrexed chemotherapy in Non-Small Cell Lung Cancer (NSCLC) EGFR mutated patients who have progressed after first-line Tyrosine Kinase Inhibitor (TKI), with the aquired resistance mutation T790M. The ARPA study is a phase II, single institution observational study aiming to evaluate the tolerability of Osimertinib in a real world population of EGFR-T790M+ NSCLC patients, with special attention to patients' perception of symptomatic Adverse Events (AEs), their impact on health-related quality of life (HRQoL) and psychological issues.
Method:
Before entry into the study, patients have been requested to perform a new tissue or liquid biopsy to confirm the T790M+ status of their tumours. Multiple previous oncologic treatments and asymptomatic brain metastases at baseline were allowed. Patients' perception of symptomatic AEs and the matched medical evaluation were performed every 21 days under continuous treatment with dedicated questionnaires which mainly evaluated the HRQoL, until discontinuation. The psychological assessments include changes in domains related to physical, mental, emotional and social functioning, depression, sleep quality and distress. In case of documented clinical benefit, the study allows to patients to remain on treatment beyond progression.
Result:
From February 2016, a total of 34 patients have been evaluated: 2 of them were registered as screening failures for symptomatic brain metastases and lack of compliance, respectively. The 32 patients enrolled have a median age of 67,6 years (range 40-84 years), are predominantly female (65,6%), with ECOG performance status 0 (68,7%) and a non-smoking history (75,0%). Activating EGFR mutation at diagnosis have been described on exon 19 and 21 in 62,5% and 28,1% of cases, respectively. Only four patients had brain metastases at study entry. Osimertinib has been used as second-line treatment, after failure of first-line TKI, in 78,1% of cases. On the date of 1 June 2017, ten patients have interrupted the treatment for disease progression, with a median duration of therapy equal to 6,69 months (range 2,80-11,20 months).
Conclusion:
Data concerning the tolerability of treatment with Osimertinib in EGFR-T790M+ NSCLC patients, their perception of symptomatic AEs together with the psychological issues evaluated in the ARPA study, are not mature. Great expectations come from this study which reflects a real world population, and the hope of the investigators is to highlight the critical aspects for patients in order to better manage their treatment and the psychological issues.
-
+
P3.06 - Epidemiology/Primary Prevention/Tobacco Control and Cessation (ID 722)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Epidemiology/Primary Prevention/Tobacco Control and Cessation
- Presentations: 1
- Moderators:
- Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P3.06-003 - What Do the Children Think about Smoking and How Are They Helped in Prevention? (ID 8815)
09:30 - 09:30 | Author(s): M.V. Pacchiana
- Abstract
Background:
Despite a lot of reports on the harmful effects of smoking on health, according to DOXA (Italian Institute of Health survey, 2016), most of people smoke the first cigarette between age 15 and age 17 (56.8%). The aim of this study was to evaluate the attitudes and knowledge of school-age children about cigarette smoking
Method:
Within the national primary prevention campaign “Questa non me la fumo” supported and promoted by WALCE we asked to teachers to administer a dedicated questionnaire to pupils. 724 questionnaires were analyzed between September 2016 and May 2017: 365 from 9 years-old primary-school pupils and 359 from 10 years-old Primary-school pupils ( 357 male: 49.3%).
Result:
66% of pupils believes that a program of intervention might be useful as prevention action; however, the perception about smoke is that harms only those who smoke, improves sports performances and can help to lose weight in 28%, 1.8% and 5.1 % of cases, respectively. Among the smoking disadvantages, pupils describe bad breath (74.3%) and yellow teeth (70.1%), without reporting hair and muscle damage. 82.2% of students declare "I will never smoke", but 7.8% of them "the curiosity to try". Considering the living environment, it resulted that 44% of parents, 20% of grandparents, 21% of teachers, and 8% of peers smoke; however, most parents talk of smoking damage to their children (72%). Answers to “In your opinion, is it possible to quit smoking?” are encouraging: 76.2% responded “Yes” while “No” in 23.8% of cases. According to age, the reason "to be cool" why starting smoking was reported in 48.2% and 55%, in the fourth and firth grade of Primary school, respectively. Other reasons frequently reported were: “to imitate adults” and “to try”. When asked, “What do you think is more dangerous for you?”, “smoking a cigarette” was the most frequent (78%) among heterogeneous responses such as to travel by hitchhiking or skydiving .
Conclusion:
These results highlight the awareness of children about the deleterious effect of smoke on health, but areas of greatest vulnerability emerged, such as poor knowledge about the smoking effects on some parts of the body or the consequences of passive smoking. Notably, children live with adults (family and school educators) but also with peers who smoke and this is worrying if we consider that the main reason for adolescent to start smoking attitude is emulation. These data emphasize the need to implement specific prevention programs also in primary school.
